Market Newsdesk

Investors with losses are encouraged to contact the firm before November 24, 2020; click


here


to submit trade information

​LOS ANGELES, Nov. 20, 2020 (GLOBE NEWSWIRE) — The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of BioMarin Pharmaceutical, Inc. (NYSE: BMRN) investors that acquired shares between February 28, 2020 and August 18, 2020. Investors have until November 24, 2020 to seek an active role in this litigation.

Investors are encouraged to contact attorney Lesley F. Portnoy, to determine eligibility to participate in this action, by phone 310-692-8883 or email, or click here to join the case.

It is alleged in the complaint that throughout the class period BioMarin issued materially misleading and/or false statements and/or failed to disclose that: (i) differences between the Phase 1/2 and Phase 3 study of valoctocogene roxaparvovec, an investigational adenoassociated virus gene therapy, limited the reliability of the Phase 1/2 study to support valoctocogene roxaparvovec’s durability of effect; (ii) as a result, it was foreseeable that the Biologics License Application for valoctocogene roxaparvovec would not be approved by the U.S. Food and Drug Administration without additional data; and (iii) as a result, the Company’s public statements were materially misleading and false at all relevant times, as a result.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 24, 2020.

Please visit our website to review more information and submit your transaction information.

The Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
[email protected]
310-692-8883
www.portnoylaw.com

Attorney Advertising

Camp Pendleton, CA, Nov. 20, 2020 (GLOBE NEWSWIRE) — Semper Fi & America’s Fund today announced the successful completion of their 12th annual Holiday Ornament Packing Party. Each year, this initiative brings together hundreds of volunteers from the greater Washington, D.C. metropolitan area for an event to package thousands of holiday ornaments that are shipped to U.S. service members, veterans and their families living or stationed around the world. Due to COVID-19 restrictions, this year’s party took place virtually in the homes of volunteers.

The packaged ornaments will be delivered this Sunday, November 22 between 8am-12pm EST at the General Lewis B. “Chesty” Puller VFW Post #1503 on 14631 Minnieville Road in Dale City, Virginia. Interested media are invited to attend to film the packing of the ornaments in the truck, which will then be sent for mailing and distribution.

“This event is our official kick-off to the holiday season at The Fund and although it had a different look and feel this year, we are always excited to spread holiday cheer in any way possible” said Karen Guenther, President, CEO and Founder of Semper Fi and American’s Fund.

This year, more than 17,000 ornaments will be mailed to service members, veterans and their families from every branch of the Armed Forces who have been wounded, ill or injured since September 11, 2001. Each ornament has a holiday design with The Fund’s logo. Volunteers included Semper Fi & America’s Fund case managers, staff and volunteers.

“Each year these ornaments arrive into the home of our service members and are hung on their family trees. It is a tangible symbol of their sacrifices will always be remembered. Whether it’s the holidays or any day, we want servicemembers, veterans and their families to know that they will never be alone,” added Guenther.

About Semper Fi & America’s Fund:

Semper Fi & America’s Fund provides immediate financial assistance and lifetime support for veterans during their time of recovery and transition back into civilian life. Since 2004, the Fund has issued $230 million in assistance to 25,000 service members, with an unprecedented 24-to-72-hour turnaround for funds to be issued after a grant is approved. Case Managers work one-on-one with service members and veterans to understand and support their individual needs now and throughout their lifetimes. The Fund keeps its overhead low in order to have the greatest impact on the lives of veterans and their families and has been awarded the highest ratings from watchdog groups: A+ from CharityWatch (one of only two Veteran nonprofits to receive their highest rating), a Charity Navigator 4-Star rating for ten consecutive years (an achievement attained by only 2% of rated charities), and the Platinum Seal of Transparency from GuideStar. Learn more at TheFund.org.

John Schiavi
Semper Fi & America's Fund 
781-354-6826
[email protected]

SEATTLE, Nov. 20, 2020 (GLOBE NEWSWIRE) — Accolade, Inc. (NASDAQ: ACCD), which provides personalized, technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits, will participate in the Piper Sandler 32^nd Annual Virtual Healthcare Conference, including a fireside chat presentation, on Tuesday, December 1, 2020. An audio replay and related presentation materials will be available at ir.accolade.com.

About Accolade, Inc.

Accolade provides personalized health and benefits solutions designed to empower every person to live their healthiest life. Using a blend of cloud-based technologies, specialized support from Accolade Health Assistants® and Clinicians, and integrated data and programs across mobile, online and phone, Accolade navigates people through the healthcare system with trust, empathy and ease. Employers offer Accolade to employees and their families as the single place to turn for all health, healthcare, and benefits questions or concerns, increasing their engagement in benefits and connecting them to high-quality providers and care. By empowering members to make better decisions about their health, Accolade can support members in lowering the cost and complexity of healthcare while achieving consumer satisfaction ratings over 90 percent and an NPS of 60.

Investor Contact:

Todd Friedman, Investor Relations, 484-532-5200, [email protected]

Asher Dewhurst, Investor Relations, 443-213-0503, [email protected]

Media Contact:

Megan Torres, Public Relations, 206-679-9630, [email protected]

Source: Accolade

Supporting the latest 5G devices, Rogers 5G is now available in parts of Winnipeg and Brandon

Powered exclusively by Ericsson, Rogers 5G will change the way Manitoba residents and businesses connect to the world around them

WINNIPEG, Manitoba, Nov. 20, 2020 (GLOBE NEWSWIRE) — Rogers Communications today announced that it has turned on its 5G service on Canada’s most trusted and reliable network¹ in Winnipeg and Brandon, Manitoba.

Customers in these locations on Rogers Infinite and Rogers for Business Shared Unlimited Data plans with compatible 5G devices will now have access to this next generation wireless technology. More than 2.2 million Canadians are on 5G-ready Rogers Infinite unlimited data plans.

Including these communities, Rogers 5G network powered by Ericsson, now reaches a total of 134 cities and towns across the country offering 10x more coverage than any other carrier. See full 5G coverage map here.

“The arrival of 5G in Manitoba will change the way we live, work and do business here,” said Larry Goerzen, President of Prairies and Alberta, Rogers Communications. “5G represents a massive technological transformation that will connect everything in our world from people and machines, to homes and cities. Beyond that, strong digital infrastructure and this next generation technology are critical to fuel productivity and innovation in the future as we reset the competitive landscape in Manitoba and for Canada, globally.”

5G will introduce new capabilities that are significantly more advanced than previous generations of wireless technology. Over the next several years, 5G will transform businesses and industries with increased speed and capacity, more efficient use of spectrum and lower latency. 5G will also support a massive increase in the number of connected devices that require near instantaneous access for applications like augmented and virtual reality, smart cities, robotics and driverless vehicles.

“On behalf of the Manitoba government, we welcome the expansion of Rogers 5G network into Winnipeg and Brandon, along with the benefits it will bring to our economy and communities,” said Hon. Ralph Eichler, Manitoba Minister of Economic Development and Training. “This expansion will bring new technology to our businesses and contribute to Manitoba’s long-term competitiveness.”

In addition to providing Canadians with the latest technology, wireless industry investments in 5G networks are expected to contribute an estimated $40 billion annually to the country’s economy and 250,000 permanent new jobs by 2026.³

“We are extremely pleased to see business investment in our Province towards more robust technology for individuals and businesses alike and we’re specifically thrilled to see Brandon included in Rogers map of 5G communities,” said Mayor of Brandon, Rick Chrest.

Rogers has invested over $30 billion over the past 35 years to build Canada’s most trusted and reliable wireless network.¹ In 2020, the company was awarded the best wireless network in Canada for the second year in a row by umlaut, the global leader in mobile network testing and benchmarking. Rogers is also ranked number one in the West, including Manitoba, and Ontario in the J.D. Power 2020 Canada Wireless Network Quality Study. A recent 2020 Ookla Speedtest report found Rogers wireless network delivers the most consistent speeds of any national wireless network in Canada.

About Rogers

Rogers is a proud Canadian company dedicated to making more possible for Canadians each and every day. Our founder, Ted Rogers, purchased his first radio station, CHFI, in 1960. We have grown to become a leading technology and media company that strives to provide the very best in wireless, residential, sports, and media to Canadians and Canadian businesses. Our shares are publicly traded on the Toronto Stock Exchange (TSX: RCI.A and RCI.B) and on the New York Stock Exchange (NYSE: RCI). If you want to find out more about us, visit about.rogers.com.

For more information

[email protected]

1-844-226-1338

¹ Most Reliable based on umlaut performance benchmark audit of Canadian mobile networks, June 2020; Most Trusted based on total wireless subscribers
² Largest based on total square kilometers of Rogers 5G coverage compared to published coverage of other national networks
³ https://www.accenture.com/_acnmedia/PDF-112/Accenture-Accelerating-5G-in-Canada-PoV-2019.pdf#zoom=50

MALVERN, Pa., Nov. 20, 2020 (GLOBE NEWSWIRE) — Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will participate in a fireside chat as part of the Piper Sandler 32nd Annual Virtual Healthcare Conference, being held December 1-3, 2020.

The pre-recorded fireside chat can be accessed beginning November 23, 2020, from the Investors page of Galera’s website, investors.galeratx.com, and will remain available for 60 days following the conference.

About Galera Therapeutics

Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. Galera’s lead product candidate is avasopasem manganese (GC4419), a highly selective small molecule superoxide dismutase (SOD) mimetic initially being developed for the reduction of radiation-induced severe oral mucositis (SOM). Avasopasem is being studied in the Phase 3 ROMAN trial to assess its ability to reduce the incidence and severity of SOM induced by radiotherapy in patients with locally advanced head and neck cancer (HNC), its lead indication. It is also being studied in the EUSOM Phase 2a multi-center trial in Europe assessing the safety of avasopasem in patients with HNC undergoing standard-of-care radiotherapy, the AESOP Phase 2a trial to assess its ability to reduce the incidence of esophagitis induced by radiotherapy in patients with lung cancer, and a Phase 2 trial in hospitalized patients who are critically ill with COVID-19. A pilot Phase 1/2 trial of avasopasem in combination with stereotactic body radiation therapy (SBRT) in patients with locally advanced pancreatic cancer has completed enrollment and reported interim results, with follow-up ongoing. The FDA granted Fast Track and Breakthrough Therapy designations to avasopasem for the reduction of SOM induced by radiotherapy. Galera’s second dismutase mimetic product candidate, GC4711, is being developed specifically to augment the anti-cancer efficacy of SBRT, and is currently being studied in the GRECO-1 Phase 1/2 clinical trial in combination with SBRT in patients with non-small cell lung cancer. Galera is headquartered in Malvern, PA. For more information, please visit www.galeratx.com.

Investor Contacts:

Christopher Degnan
Galera Therapeutics, Inc.
610-725-1500
[email protected]

Jennifer Porcelli
Solebury Trout
646-378-2962
[email protected]

Media Contact:

Heather Anderson
6 Degrees
919-827-5539
[email protected]

Voorhies has
Extensive Business and Industry Experience in Diagnostics & Monitoring  

Mountain View, CA, Nov. 20, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a life sciences company developing biotechnologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming, today announced that it has appointed Anthony Voorhies as Head of Business Development for AditxtScore™.

Mr. Voorhies has commercialized a broad range of diagnostic tools, biomarkers, and FDA-cleared imaging and functional testing medical devices and has collaborated with some of the world’s preeminent research institutions, conducting training for research protocols and introducing complementary diagnostics into clinical care models. He has spent over a decade building and managing high performance teams in the health sciences industry, growing them from early stage to high-growth performance. Prior to joining Aditxt, Anthony helped deploy medical device, diagnostics, and COVID-19 strategies for Calroy Health Sciences LLC, and previously was the U.S. Product Director for Itamar Medical, Inc.

Amro Albanna, Co-Founder and CEO of Aditxt, commented, “AditxtScore is well-positioned for growth and Anthony is the right leader to move the opportunity forward. He has the extensive business and industry background that’s needed to launch and grow the AditxtScore™ platform as an immune monitoring service and shares our vision for the platform’s potential to transform immune diagnosis from reactive testing to proactive monitoring. We welcome him to our Aditxt family and look forward to realizing that vision together.”

About Aditx Therapeutics

Aditxt is developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming. The immune monitoring technology is designed to provide a personalized comprehensive profile of the immune system. The immune reprogramming technology is currently at the pre-clinical stage and is designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. For more information, please visit: www.aditxt.com

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Forward looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company’s ongoing and planned product development; the Company’s intellectual property position; the Company’s ability to develop commercial functions; expectations regarding product launch and revenue; the Company’s results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as those risks more fully discussed in the section entitled “Risk Factors” in the Company’s prospectus, dated September 1, 2020, that was filed with the Securities and Exchange Commission under File No. 333-248491, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s subsequent filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations:
PCG Advisory
Jeff Ramson
Chief Executive Officer
[email protected]
646-762-4518
www.aditxt.com

Investors with losses are encouraged to contact the firm before November 24, 2020; click


here


to submit trade information
​

LOS ANGELES, Nov. 20, 2020 (GLOBE NEWSWIRE) — The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Peabody Energy Corporation (NYSE: BTU) investors that acquired shares between April 3, 2017 and October 28, 2019. Investors have until November 24, 2020 to seek an active role in this litigation.

Investors are encouraged to contact attorney Lesley F. Portnoy, to determine eligibility to participate in this action, by phone 310-692-8883 or email, or click here to join the case.

According to the Complaint, Peabody made misleading and/or false statements to the market. At its North Goonyella mine, Peabody failed to follow appropriate safety controls, placing it at a heightened risk of being shut down. Peabody followed a low-cost plan to restart operations that did not address environmental and safety concerns. The Queensland Mines Inspectorate was likely to mandate a more costly, safer approach. Based on this difference, Peabody suffered further delays in reopening the mine. Peabody’s public statements were materially misleading and false throughout the class period, based on these facts. Investors suffered damages when the market learned the truth about Peabody.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 24, 2020.

Please visit our website to review more information and submit your transaction information.

The Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
[email protected]
310-692-8883
www.portnoylaw.com

Attorney Advertising

CAMBRIDGE, Mass., Nov. 20, 2020 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance, today announced that management will participate in the following upcoming virtual investor conferences:

• Piper Sandler 32nd Annual Healthcare Conference 
  Prerecorded fireside chat available on Monday, November 23, 2020 at 10:00 a.m. ET; Institutional investor meetings to be conducted on Tuesday, December 1, 2020

• 3rd Annual Evercore ISI
  HealthCONx
  Conference  
  Fireside chat on Thursday, December 3, 2020 from 3:55 – 4:15 p.m. ET

The events will be available via webcast through the “Events & Presentations” page of the “Investors & Media” section of the company’s website at www.praxismedicines.com. Replays of the webcasts will be available for 90 days following the events.

About Praxis

Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance. Praxis is applying insights into the genetic mutations that drive excitation-inhibition imbalance in diseases to select biological targets for severe pediatric epilepsies and more broadly for prevalent psychiatric diseases and neurologic disorders. Praxis has established a broad portfolio, including five disclosed programs across multiple central nervous system disorders including, depression, epilepsy, movement disorders and pain syndromes, with three clinical-stage product candidates.

Investor Contact:

Alex Kane
Praxis Precision Medicines
[email protected]
617-300-8481

Media Contact:

Ian Stone
Canale Communications
[email protected]
619-849-5388

SAN FRANCISCO, California, Nov. 20, 2020 (GLOBE NEWSWIRE) — Innovator and creator of first-to-market skincare solutions, Peace Out Skincare is launching its award-winning Acne Treatment Dot in Canada with exclusive partner Sephora. The patent-pending Acne Dot disrupted the skincare market when it launched in the US in 2017 by combining hydrocolloid polymer technology with active anti-acne fighting and healing ingredients for the very first time. In Canada, all skincare used to treat medical conditions, such as acne, are rigorously vetted by Health Canada. The submission must include consumer studies that prove the efficacy and quality of the product. Peace Out Skincare is the first and only brand to launch a patch that is certified to help heal acne in Canada.

“Peace Out Skincare’s number one priority is creating effective, clean, and fun skincare treatments that actually work,” stated Enrico Frezza, Founder and CEO of Peace Out Skincare. “Health Canada’s authorization further validates Peace Out’s Acne Dot as the first and only approved acne treatment dot in Canada.”

On his quest for a solution that worked for his own acne, Frezza spent three years developing the initial Acne Dot. Subsequently, Frezza continued to invent industry-first skincare products—Wrinkles, Pores, Puffy Eyes, Dark Spots and more—all utilizing novel delivery systems and incorporating unique blends of high quality clean ingredients.

The international brand began selling a limited selection of its products through Sephora Canada in May of this year. The Peace Out Acne Treatment Dot will hit Sephora.ca today, November 20th and in stores November 27th retailing for $25 CAD.

Peace Out Skincare


Beauty-technology leader, Peace Out Skincare is committed to creating first-to-market, innovative solutions for everyday skin problems. Launched in 2017, the brand is known for combining cutting edge delivery systems with clean, effective, high-quality ingredients. Peace Out Skincare celebrates their ‘skin champ’ community by promoting acne positivity and skin inclusivity.

Media Contact
Stephanie Kraeutler
The Lead PR
[email protected]
212.584.5668

Investors with losses are encouraged to contact the firm before November 24, 2020; click


here


to submit trade information

LOS ANGELES, Nov. 20, 2020 (GLOBE NEWSWIRE) — The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Garrett Motion, Inc. (NYSE: GTX) investors that acquired shares between October 1, 2018 and September 18, 2020. Investors have until November 24, 2020 to seek an active role in this litigation.

Investors are encouraged to contact attorney Lesley F. Portnoy, to determine eligibility to participate in this action, by phone 310-692-8883 or email, or click here to join the case.

Garrett Motion Inc. operates as an automobile technology provider. The Company offers turbocharging, electric boosting, and automotive software solutions. Garrett Motion serves customers worldwide.

The investigation focuses on whether the Company misled investors regarding the Company’s balance sheet risks, specifically the Company’s liabilities and exposure to certain claims by Honeywell. On August 26, 2020, the Company disclosed, “Garrett’s leveraged capital structure poses significant challenges to its overall strategic and financial flexibility and may impair its ability to gain or hold market share in the highly competitive automotive supply market, thereby putting Garrett at a meaningful disadvantage relative to its peers.”

On this news, the Company’s share price fell significantly, causing economic harm to investors.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 24, 2020.

Please visit our website to review more information and submit your transaction information.

The Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
[email protected]
310-692-8883
www.portnoylaw.com

Attorney Advertising